AAVANTIBIO
Dead / Abandoned — Abandoned — no statement of use filed (as of 08 May 2023)
What this means for you
This application is over — abandoned 08 May 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88359975
- Mark type
- Word mark
- Filed
- 27 Mar 2019
- Published for opposition
- 11 Feb 2020
- Abandoned
- 08 May 2023
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 005 — Pharmaceuticals: Biological treatments, namely, biological preparations, for use for clinical, medicinal and the therapeutic treatment of Friedreich's Ataxia and genetic disorders; biological preparations for the treatment of Friedreich's Ataxia and genetic disorders; Biospecific reagents for medical use, for use in immunotherapy for the treatment of Friedreich's Ataxia and genetic disorders; Biological preparations for use in immunotherapy for the treatment of Friedreich's Ataxia and genetic disorders; Biological preparations, namely, biological drugs in the nature of gene therapy products for use for clinical, medicinal and therapeutic treatment of Friedreich's Ataxia; biological preparations, namely, biological drugs in the nature of gene therapy products for treatment of genetic diseases and Friedreich's Ataxia; biological preparations, namely, biological drugs in the nature of gene therapy products for use in treating Friedreich's Ataxia and autoimmunity disorders and diseases; biological preparations, namely, gene therapy products in the nature of therapeutic pharmaceuticals for the treatment of Friedreich's Ataxia, autoimmune, immune system diseases and disorders; pharmaceutical preparations for human use for the treatment of Friedreich's Ataxia; Therapeutic pharmaceutical preparations and medical diagnostic agents and preparations for use in therapies for Friedreich's Ataxia and autoimmunity, all of the foregoing for medical use; Therapeutic pharmaceutical preparations and diagnostic agents, preparations and substances for medical purposes for targeting application to immunotherapies and therapeutic and diagnostic agents
Owner
- AAVANTIBIO, INC., Cambridge, MA, US
- AAVANTIBIO, INC., GAINESVILLE, FL, US
- Aavanti LLC, Gainesville, FL, US
Prosecution history
- 08 May 2023 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 08 May 2023 — ABANDONMENT - NO USE STATEMENT FILED
- 22 Feb 2023 — ASSIGNED TO EXAMINER
- 04 Oct 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Oct 2022 — SOU EXTENSION 5 GRANTED
- 27 Sept 2022 — SOU EXTENSION 5 FILED
- 27 Sept 2022 — SOU TEAS EXTENSION RECEIVED
- 07 Apr 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Apr 2022 — SOU EXTENSION 4 GRANTED
- 05 Apr 2022 — SOU EXTENSION 4 FILED
- 05 Apr 2022 — SOU TEAS EXTENSION RECEIVED
- 18 Sept 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 Sept 2021 — SOU EXTENSION 3 GRANTED
- 16 Sept 2021 — SOU EXTENSION 3 FILED
- 16 Sept 2021 — SOU TEAS EXTENSION RECEIVED